Madrigal Pharmaceuticals today released strongly positive results for its NASH drug Resmetirom which are far superior to what almost anyone expected.

Their strongly positive results were across the board for the pivotal MAESTRO-NASH study in patients with fibrotic NASH. Resmetirom achieved highly statistically significant results in two key primary endpoints with both daily oral doses, 80 mg and 100 mg, relative to placebo. Specifically:

We presented a poster of the State of NAFLD/NASH Care in America survey at the annual conference of the AASLD, the American Association for the Study of Liver Disease, last week. If you would like to look at a pdf click on the image below.

Of shoes and ships, of sealing wax and cabbages and kings -- and NAFLD and NASH and how we treat those things.

The Foundation's recent State of NAFLD/NASH Care in America survey highlighted the problem of the lack of understanding of liver disease, even after a visit with a specialist. How do we manage a disease when only 13% of patients understand it even after seeing a specialist?

The Fatty Liver Foundation (FLF) is excited to announce preliminary findings from The State of NAFLD/NASH Care in America™, a first-of-its-kind national initiative that aims to make a big impact within the NAFLD/NASH community by surveying the lived experiences of adults with NAFLD/NASH in the United States and fostering the continuous development and integration of actionable solutions to improve the diagnosis, treatment, care, and support for people with NAFLD/NASH.

This note is an invitation to a webinar about managing social isolation. It will be September 28th, 12:00 EST.

I'll explain below but click this link to register.

No one plans to become sick and alone, cut off from meaningful human contact and dying slowly. Humor me for a bit and picture yourself being in solitary confinement and being quite ill. Your cell bars are not metal but the pain and fatigue of chronic illness can become so heavy that breaking free is very difficult.

We recently offered a flash survey to our members asking for their views on whether the term "fatty" included in the name of nonalcoholic fatty liver disease (NAFLD) was stigmatizing.  Here is a link to the results.

Results of the Flash Survey on Stigma in the name NAFLD